浙江知一药业

Zhejiang Zhiyi Pharmaceutical (SIPCO) is a high-tech pharmaceutical company specializing in the research, development, and manufacturing of high-quality inhalation formulations. Founded in 2018 by renowned inhalation formulation expert Dr. Wang Zhaolin, the company focuses on respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. SIPCO has established three major inhalation drug delivery platforms: Dry Powder Inhalers (DPI), Nebulizers, and Nasal Sprays. Its pipeline includes generic and improved inhalation therapies, such as Budesonide Inhalation Suspension and combination therapies involving tiotropium bromide, salmeterol, and fluticasone. The company operates a manufacturing and R&D facility in Fuyang, Hangzhou, Zhejiang Province, China.